Warfarin Toxicity and Individual Variability—Clinical Case
AbstractWarfarin is a widely used anticoagulant in the treatment and prevention of thrombosis, in the treatment for chronic atrial fibrillation, mechanical valves, pulmonary embolism, and dilated cardiomyopathy. It is tasteless and colorless, was used as a poison, and is still marketed as a pesticide against rats and mice. Several long-acting warfarin derivatives—superwarfarin anticoagulants—such as brodifacoum, diphenadione, chlorophacinone, bromadiolone, are used as pesticides and can produce profound and prolonged anticoagulation. Several factors increase the risk of warfarin toxicity. However, polymorphisms in cytochrome P450 genes and drug interactions account for most of the risk for toxicity complications. Each person is unique in their degree of susceptibility to toxic agents. The toxicity interpretation and the health risk of most toxic substances are a subject of uncertainty. Genetically determined low metabolic capacity in an individual can dramatically alter the toxin and metabolite levels from those normally expected, which is crucial for drugs with a narrow therapeutic index, like warfarin. Personalized approaches in interpretation have the potential to remove some of the scientific uncertainties in toxicity cases. View Full-Text
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Piatkov, I.; Rochester, C.; Jones, T.; Boyages, S. Warfarin Toxicity and Individual Variability—Clinical Case. Toxins 2010, 2, 2584-2592.
Piatkov I, Rochester C, Jones T, Boyages S. Warfarin Toxicity and Individual Variability—Clinical Case. Toxins. 2010; 2(11):2584-2592.Chicago/Turabian Style
Piatkov, Irina; Rochester, Colin; Jones, Trudi; Boyages, Steven. 2010. "Warfarin Toxicity and Individual Variability—Clinical Case." Toxins 2, no. 11: 2584-2592.